Glifil M Forte 5mg/500mg Tablet is a combination oral hypoglycemic agent containing Glibenclamide 5mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glibenclamide, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle tissues. The synergistic action of these two agents helps achieve better glycemic control in patients inadequately managed by diet and exercise alone or monotherapy. Glifil M Forte is typically prescribed when single-agent therapy is insufficient, offering the advantage of dual mechanisms addressing both insulin deficiency and insulin resistance. It is essential to monitor blood glucose levels regularly and adjust dosage accordingly to minimize the risk of hypoglycemia, particularly due to Glibenclamide. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or conditions predisposing to lactic acidosis. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and rarely, lactic acidosis. Glifil M Forte should be used as part of a comprehensive diabetes management plan, including diet, exercise, and regular medical supervision.